Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.44 |
| ▸ | CCR9 | P51686 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TCF4 | P15884 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10223636 | 0.88 | CCR9 (0.46) | GPR27CCR9CCR2HTTMEN1 | |
| SCHEMBL10222598 | 0.86 | CCR9 (0.49) | GPR27CCR9CCR2HTTMEN1 | |
| SCHEMBL305833 | 0.86 | CCR9 (0.48) | GPR27CCR9CCR2HTTBDKRB1 | |
| SCHEMBL10223607 | 0.85 | CCR9 (0.48) | GPR27CCR9CCR2CA2 | |
| SCHEMBL10223677 | 0.84 | CCR9 (0.44) | CCR9CCR2HTTMEN1KMT2A | |
| SCHEMBL10223726 | 0.82 | CCR9 (0.47) | GPR27CCR9CCR2HTTMEN1 | |
| SCHEMBL10223623 | 0.82 | CCR9 (0.49) | GPR27CCR9CCR2HTTMEN1 | |
| SCHEMBL10223688 | 0.81 | CCR9 (0.53) | CCR9EGFRCCR2HTTMEN1 | |
| SCHEMBL10223696 | 0.81 | CCR9 (0.49) | GPR27CCR9CCR2HTTMEN1 | |
| SCHEMBL10223649 | 0.79 | CCR9 (0.48) | CCR9CCR2MEN1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX INC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8519135-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8093247-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093247-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. | 2010-03-04 | — | — | US | disclosed |
| US-7622583-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622583-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | GPR27 134/4885CCR9 2/4885EGFR 1742/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | GPR27 367/4885CCR9 12/4885EGFR 2870/4885 |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | GPR27 134/4885CCR9 2/4885EGFR 1742/4885 |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CCR2, CXCR2, CCR1 | GPR27 112/4885CCR9 15/4885EGFR 1940/4885 |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | GPR27 134/4885CCR9 2/4885EGFR 1742/4885 |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | GPR27 134/4885CCR9 2/4885EGFR 1742/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | GPR27 134/4885CCR9 2/4885EGFR 1742/4885 |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | GPR27 134/4885CCR9 2/4885EGFR 1742/4885 |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | GPR27 134/4885CCR9 2/4885EGFR 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.